CAR--话题@MedSci

#CAR-#

459篇内容 | 2617人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1781333, encodeId=206e1e8133338, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿, objectType=article, longId=184904, objectId=574418490463, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=574418490463, replyNumber=0, likeNumber=64, createdTime=2020-08-03, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=574418490463, moduleTitle=百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=574418490463)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781356, encodeId=568f1e8135654, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=59岁患者接受CAR-T细胞免疫疗法后超过3年无癌症标志物, objectType=article, longId=192035, objectId=9c5119203548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c5119203548, replyNumber=0, likeNumber=98, createdTime=2020-06-25, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c5119203548, moduleTitle=59岁患者接受CAR-T细胞免疫疗法后超过3年无癌症标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c5119203548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781322, encodeId=966f1e81322d3, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=病例分享 | CD19抗原丢失导致CAR-T治疗后快速进展, objectType=article, longId=182587, objectId=06d418258ee0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06d418258ee0, replyNumber=0, likeNumber=67, createdTime=2019-12-25, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06d418258ee0, moduleTitle=病例分享 | CD19抗原丢失导致CAR-T治疗后快速进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06d418258ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781332, encodeId=c9b01e813324c, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T细胞疗法在美国血液学会ASH上大放异彩, objectType=article, longId=184849, objectId=fa79184849b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa79184849b1, replyNumber=0, likeNumber=76, createdTime=2020-11-11, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa79184849b1, moduleTitle=CAR-T细胞疗法在美国血液学会ASH上大放异彩, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa79184849b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781320, encodeId=d87a1e81320e7, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Autolus的快速解离型CAR-T细胞疗法治疗急性淋巴细胞白血病，获FDA孤儿药物指定, objectType=article, longId=182512, objectId=6d2018251202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d2018251202, replyNumber=0, likeNumber=75, createdTime=2020-10-05, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d2018251202, moduleTitle=Autolus的快速解离型CAR-T细胞疗法治疗急性淋巴细胞白血病，获FDA孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d2018251202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781290, encodeId=8dfe1e81290a4, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=J Exp Med：首次直观地观察到CAR-T细胞抵御血液癌症的过程, objectType=article, longId=164139, objectId=f4d7164139dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4d7164139dd, replyNumber=0, likeNumber=108, createdTime=2020-03-19, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4d7164139dd, moduleTitle=J Exp Med：首次直观地观察到CAR-T细胞抵御血液癌症的过程, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4d7164139dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781310, encodeId=b3441e8131009, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=全球**获批的CAR-T疗法临床试验申请在华获得受理, objectType=article, longId=177718, objectId=5b7e1e771841, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b7e1e771841, replyNumber=0, likeNumber=59, createdTime=2019-11-30, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b7e1e771841, moduleTitle=全球**获批的CAR-T疗法临床试验申请在华获得受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b7e1e771841)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781339, encodeId=47ea1e813394a, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=“即用型”CAR-T疗法：权宜之计还是真的未来？, objectType=article, longId=186250, objectId=34b618625008, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34b618625008, replyNumber=0, likeNumber=60, createdTime=2020-09-10, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34b618625008, moduleTitle=“即用型”CAR-T疗法：权宜之计还是真的未来？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34b618625008)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781314, encodeId=accf1e81314b4, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Sci Trans Med：新型CAR-T首换新靶点，有望告别血癌淋巴癌复发！, objectType=article, longId=180169, objectId=57f3180169bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57f3180169bd, replyNumber=0, likeNumber=59, createdTime=2020-08-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57f3180169bd, moduleTitle=Sci Trans Med：新型CAR-T首换新靶点，有望告别血癌淋巴癌复发！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57f3180169bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781303, encodeId=f55d1e8130302, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=B细胞淋巴瘤治疗：即使CAR-T疗法失败，还有双特异性抗体REGN1979, objectType=article, longId=168604, objectId=b8a016860474, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8a016860474, replyNumber=0, likeNumber=73, createdTime=2019-10-04, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8a016860474, moduleTitle=B细胞淋巴瘤治疗：即使CAR-T疗法失败，还有双特异性抗体REGN1979, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8a016860474)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781348, encodeId=8e931e81348b9, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=4.56亿美元，吉利德CAR-T疗法Yescarta2019年销售业绩披露, objectType=article, longId=187885, objectId=d23418e8852c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d23418e8852c, replyNumber=0, likeNumber=92, createdTime=2020-04-23, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d23418e8852c, moduleTitle=4.56亿美元，吉利德CAR-T疗法Yescarta2019年销售业绩披露, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d23418e8852c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781317, encodeId=688b1e81317ab, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=活体药物还是医疗技术——十字路口的国内CAR-T企业, objectType=article, longId=181058, objectId=1d6218105892, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d6218105892, replyNumber=0, likeNumber=55, createdTime=2020-09-18, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d6218105892, moduleTitle=活体药物还是医疗技术——十字路口的国内CAR-T企业, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d6218105892)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781293, encodeId=570c1e81293cc, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=PNAS：基于纳米抗体的CAR-T细胞有望治疗实体瘤, objectType=article, longId=164283, objectId=a78616428307, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a78616428307, replyNumber=0, likeNumber=78, createdTime=2019-07-19, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a78616428307, moduleTitle=PNAS：基于纳米抗体的CAR-T细胞有望治疗实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a78616428307)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781327, encodeId=598c1e8132792, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=总缓解率达100% ，金斯瑞子公司传奇生物公布CAR-T美国临床试验数据, objectType=article, longId=184481, objectId=a42e1844818f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a42e1844818f, replyNumber=0, likeNumber=78, createdTime=2020-08-18, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a42e1844818f, moduleTitle=总缓解率达100% ，金斯瑞子公司传奇生物公布CAR-T美国临床试验数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a42e1844818f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781294, encodeId=ed2c1e81294bb, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=更精准杀伤癌细胞，中国与全球同步开展CAR-T临床试验, objectType=article, longId=164466, objectId=170216446633, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=170216446633, replyNumber=0, likeNumber=66, createdTime=2019-12-27, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=170216446633, moduleTitle=更精准杀伤癌细胞，中国与全球同步开展CAR-T临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=170216446633)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781283, encodeId=c3fb1e8128374, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=喜讯连连！科济生物再获CD19靶向的CAR-T细胞的临床试验许可, objectType=article, longId=161587, objectId=a4cf16158eac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4cf16158eac, replyNumber=0, likeNumber=88, createdTime=2019-08-31, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4cf16158eac, moduleTitle=喜讯连连！科济生物再获CD19靶向的CAR-T细胞的临床试验许可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4cf16158eac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781307, encodeId=22fc1e8130728, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Science：MIT科学家发明两亲疫苗，大幅提高CAR-T抗癌活性，将60%小鼠肿瘤完全清除, objectType=article, longId=175724, objectId=04781e5724fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04781e5724fd, replyNumber=0, likeNumber=53, createdTime=2020-05-09, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04781e5724fd, moduleTitle=Science：MIT科学家发明两亲疫苗，大幅提高CAR-T抗癌活性，将60%小鼠肿瘤完全清除, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04781e5724fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781308, encodeId=ee1f1e81308ad, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nat Biotech | 针对肿瘤抗原异质性问题，提出CAR-T与BiTEs联合的免疫疗法，产生强有力的特异性抗肿瘤效应, objectType=article, longId=176417, objectId=1f141e6417a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f141e6417a6, replyNumber=0, likeNumber=57, createdTime=2020-01-11, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f141e6417a6, moduleTitle=Nat Biotech | 针对肿瘤抗原异质性问题，提出CAR-T与BiTEs联合的免疫疗法，产生强有力的特异性抗肿瘤效应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f141e6417a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781331, encodeId=b7761e8133130, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Kite向FDA提交第二种CAR-T细胞疗法的申请，以治疗套细胞淋巴瘤, objectType=article, longId=184844, objectId=f4f518484488, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4f518484488, replyNumber=0, likeNumber=80, createdTime=2020-07-08, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4f518484488, moduleTitle=Kite向FDA提交第二种CAR-T细胞疗法的申请，以治疗套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4f518484488)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781295, encodeId=33c51e812951f, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Blood:哪些因素会影响CAR-T治疗后获得完全缓解的患者的无事件生存？, objectType=article, longId=164688, objectId=b224164688bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b224164688bf, replyNumber=0, likeNumber=66, createdTime=2019-08-04, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b224164688bf, moduleTitle=Blood:哪些因素会影响CAR-T治疗后获得完全缓解的患者的无事件生存？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b224164688bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CAR-

2020-05-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿

2020-08-03

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

59岁患者接受CAR-T细胞免疫疗法后超过3年无癌症标志物

2020-06-25

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

病例分享 | CD19抗原丢失导致CAR-T治疗后快速进展

2019-12-25

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T细胞疗法在美国血液学会ASH上大放异彩

2020-11-11

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Autolus的快速解离型CAR-T细胞疗法治疗急性淋巴细胞白血病，获FDA孤儿药物指定

2020-10-05

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

J Exp Med：首次直观地观察到CAR-T细胞抵御血液癌症的过程

2020-03-19

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

全球**获批的CAR-T疗法临床试验申请在华获得受理

2019-11-30

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

“即用型”CAR-T疗法：权宜之计还是真的未来？

2020-09-10

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Sci Trans Med：新型CAR-T首换新靶点，有望告别血癌淋巴癌复发！

2020-08-17

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

B细胞淋巴瘤治疗：即使CAR-T疗法失败，还有双特异性抗体REGN1979

2019-10-04

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

4.56亿美元，吉利德CAR-T疗法Yescarta2019年销售业绩披露

2020-04-23

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

活体药物还是医疗技术——十字路口的国内CAR-T企业

2020-09-18

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

PNAS：基于纳米抗体的CAR-T细胞有望治疗实体瘤

2019-07-19

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

总缓解率达100% ，金斯瑞子公司传奇生物公布CAR-T美国临床试验数据

2020-08-18

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

更精准杀伤癌细胞，中国与全球同步开展CAR-T临床试验

2019-12-27

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

喜讯连连！科济生物再获CD19靶向的CAR-T细胞的临床试验许可

2019-08-31

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Science：MIT科学家发明两亲疫苗，大幅提高CAR-T抗癌活性，将60%小鼠肿瘤完全清除

2020-05-09

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nat Biotech | 针对肿瘤抗原异质性问题，提出CAR-T与BiTEs联合的免疫疗法，产生强有力的特异性抗肿瘤效应

2020-01-11

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Kite向FDA提交第二种CAR-T细胞疗法的申请，以治疗套细胞淋巴瘤

2020-07-08

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

Blood:哪些因素会影响CAR-T治疗后获得完全缓解的患者的无事件生存？

2019-08-04

科室
- - 订阅+
  - 更多科室
工具
服务